NCT04967742View on ClinicalTrials.gov

A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

August 22, 2021

Study Completion Date

October 31, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

UB-612

UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.

Trial Locations (1)

Unknown

China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

Vaxxinity, Inc.

INDUSTRY

lead

United Biomedical Inc., Asia

INDUSTRY

NCT04967742 - A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine | Biotech Hunter | Biotech Hunter